Financial Performance - For the first half of 2022, the company reported operating revenue of RMB 738,305,000, an increase of 21.5% compared to RMB 607,737,000 in the same period of 2021[20]. - The profit before tax for the first half of 2022 was RMB 63,331,000, up from RMB 53,745,000 in the first half of 2021, representing an increase of 17.5%[20]. - The net profit attributable to shareholders for the first half of 2022 was RMB 38,788,000, compared to RMB 35,003,000 in the same period of 2021, reflecting an increase of 7.9%[20]. - The net profit for minority shareholders in the first half of 2022 was RMB 5,433,000, significantly higher than RMB 1,235,000 in the same period of 2021[20]. - The total gross profit for the group reached RMB 197.8 million, an increase of 28.8% compared to the same period in 2021[51]. - The gross profit margin for self-owned hospitals was 26.5%, compared to 25.6% for the same period in 2021, with overall gross profit increasing to RMB 197.8 million, a growth of 28.8%[25]. - The gross margin for the group increased to 26.8%, compared to 25.3% for the same period in 2021[51]. - The revenue from pharmaceutical sales for the six months ended June 30, 2022, was RMB 147,586,000, a 15.0% increase from RMB 128,280,000 in the previous year[175]. Assets and Liabilities - Total assets as of June 30, 2022, were RMB 2,693,723,000, an increase from RMB 2,377,968,000 as of December 31, 2021[20]. - The company’s total liabilities increased to RMB 1,339,418,000 as of June 30, 2022, compared to RMB 1,106,880,000 at the end of 2021[20]. - The company’s total equity as of June 30, 2022, was RMB 1,354,305,000, up from RMB 1,271,088,000 at the end of 2021[20]. - Accounts receivable increased to RMB 422.1 million, a 35.4% growth compared to RMB 311.8 million as of December 31, 2021[83]. - The group's bank borrowings increased to RMB 783.4 million from RMB 553.2 million as of December 31, 2021, due to new borrowings of RMB 317.5 million[85]. - The asset-liability ratio slightly increased to 49.7% from 46.5% as of December 31, 2021, mainly due to the increase in bank borrowings[92]. Operational Highlights - The group achieved revenue of RMB 738.3 million, an increase of 21.5% compared to the same period in 2021, with self-owned hospital operating revenue at RMB 683.1 million, up 21.7%[25]. - The number of outpatient visits increased to 225,032, a rise of 26.5%, with outpatient revenue reaching RMB 101.0 million, up 29.5% compared to the previous year[46]. - The group expanded its self-owned hospitals to 30, including one independent internet hospital, with total operational beds increasing to 9,558[22]. - The group reported a significant increase in billing income from self-owned hospitals to RMB 689.6 million, up RMB 111.6 million from the previous year, driven by growth in several hospitals and new acquisitions[42]. - The inpatient billing revenue was RMB 588.6 million, a 17.7% increase year-on-year, attributed to a 14.4% growth in inpatient bed days[65]. Expenses and Costs - The cost of self-owned hospital services increased to RMB 502.1 million, up from RMB 417.6 million in the previous year, with significant rises in employee benefits and medical supplies[47]. - The management expenses for the group were RMB 94.9 million, reflecting a 24.8% increase compared to the previous year[54]. - The total management expenses rose to RMB 94.9 million from RMB 76.1 million in the same period of 2021, driven by increased employee benefits and professional service fees[73]. - The group's self-owned hospital revenue cost increased to RMB 502.1 million, a 20.2% increase compared to the same period in 2021[68]. - Total finance costs increased to RMB 21.65 million, compared to RMB 17.24 million in the previous year, representing a rise of 25.0%[100]. Strategic Initiatives - The company is committed to its long-term development strategy of "Centennial Kangning" amidst ongoing healthcare payment reforms[21]. - The group plans to enhance its healthcare service capabilities and establish a multi-level, diversified healthcare service network, focusing on mental health and elderly care[23]. - The group aims to deepen the integration of industry, academia, and research to promote the development of advantageous disciplines and improve talent cultivation mechanisms[23]. - The group is actively exploring new business areas such as social psychological services and clinical trials for drugs/devices[23]. - The group is focusing on the mental health and elderly medical industries, aligning with the ongoing "Healthy China" initiative and the aging society trend[173]. Employee and Governance - The group’s total number of employees increased to 4,245 from 3,661 as of December 31, 2021, reflecting a growth of 16.0%[112]. - The average employee compensation was RMB 115.6 thousand per year, compared to RMB 98.1 thousand in the same period last year, indicating a rise of 17.9%[112]. - The company has established an equity incentive plan to motivate senior management and core technical personnel, approved at the 2017 annual general meeting[125]. - The board believes that the company has complied with all provisions of the corporate governance code during the reporting period[162]. - The company has implemented measures to control insider information disclosure to minimize the number of individuals with access to such information[156].

Financial Performance - The company's operating revenue for 2021 was RMB 1,297.43 million, an increase of 31.2% compared to RMB 989.01 million in 2020[7] - The profit before tax for 2021 was RMB 95.70 million, up from RMB 74.32 million in 2020[7] - Net profit attributable to shareholders for 2021 was RMB 44.05 million, a decrease from RMB 55.77 million in 2020[7] - The total liabilities as of December 31, 2021, were RMB 1,106.88 million, an increase from RMB 955.55 million in 2020[7] - The company achieved a total revenue of RMB 1,297.4 million in 2021, representing a 31.2% increase compared to 2020, with self-operated hospital revenue at RMB 1,202.8 million, up 28.6%[26] - The gross profit margin for self-operated hospitals improved to 25.4% in 2021 from 25.0% in 2020, with overall gross profit increasing to RMB 329.0 million, a growth of 26.6%[26] - Net profit attributable to shareholders decreased by 21.0% to RMB 44.0 million in 2021 compared to the previous year[26] - The total billing revenue for self-owned hospitals reached RMB 1,230.0 million, an increase of RMB 251.5 million or 25.7% compared to 2020, driven by growth in several hospitals and acquisitions[33] - The gross profit for self-owned hospitals increased by 20.2% to RMB 332.9 million, attributed to an increase in inpatient bed days and average spending per bed day[33] - Inpatient billing revenue was RMB 1,053.7 million, up 24.8% year-on-year, with inpatient bed days increasing by 22.3%[36] - Outpatient billing revenue rose by 31.7% to RMB 176.3 million, driven by a 45.3% increase in outpatient visits[36] Assets and Liabilities - Total assets as of December 31, 2021, were RMB 2,377.97 million, compared to RMB 2,161.28 million in 2020[7] - As of December 31, 2021, accounts receivable increased by 38.4% to RMB 311.8 million, reflecting growth in operating revenue[67] - As of December 31, 2021, the group had no investment properties, down from RMB 107.8 million as of December 31, 2020[69] - Other non-current financial assets increased to RMB 65.8 million as of December 31, 2021, from RMB 57.4 million as of December 31, 2020, reflecting a fair value increase of RMB 8.4 million[70] - Right-of-use assets rose to RMB 257.4 million as of December 31, 2021, up from RMB 232.6 million as of December 31, 2020, due to new lease agreements adding RMB 24.8 million[71] - Accounts payable decreased to RMB 69.2 million as of December 31, 2021, from RMB 72.0 million as of December 31, 2020[74] Operational Expansion - The number of medical institutions operated by the company increased from 24 at the end of 2020 to 27 at the end of 2021[11] - The number of operational beds increased from 7,438 at the end of 2020 to 8,728 at the end of 2021[11] - In 2021, the group expanded its hospital network to 27 hospitals, up from 24 in 2020, with a total of 8,728 operational beds, an increase from 7,438 beds in the previous year[19] - The group reported significant growth in its newly established hospitals, with rapid business scale growth compared to the same period last year[19] - The group successfully integrated acquired hospitals, including Wenzhou Cining Hospital and Changchun Kanglin Psychological Hospital, contributing positively to overall performance during the reporting period[19] - The group is actively developing the elderly rehabilitation medical sector, having acquired Pingyang Chang Geng Yining Hospital and established Cangnan Yining Nursing Center[20] Strategic Initiatives - The company aims to expand its influence in the mental health sector, aligning with national health strategies[9] - The group is focusing on the construction of key projects, including new hospital buildings and renovation projects, to accumulate development momentum for high-quality growth[20] - The group is exploring new business development paths through the construction of an "Internet Mental Health Platform" and integration with upstream pharmaceutical businesses[20] - The group is committed to improving medical service capabilities to meet diverse patient needs, especially in the context of increasing mental health issues[14] - The group is responding to national health strategies aimed at improving mental health services and community rehabilitation systems[15] Governance and Compliance - The company has complied with relevant laws and regulations, including the Mental Health Law and the Basic Medical and Health Promotion Law of the People's Republic of China[102] - The company has complied with the corporate governance code and maintained the minimum public float as required by Hong Kong listing rules[160][161] - The financial statements for the year ended December 31, 2021, were audited by Lixin CPA, following the resignation of PwC due to unresolved audit concerns[164] - The company appointed Lixin as its auditor on January 30, 2022, to fill the temporary vacancy left by PwC until the next annual general meeting[166] - The supervisory board has effectively monitored the company's major policies and decisions, ensuring compliance with relevant laws and regulations[173] - The board consists of seven members, including two executive directors, two non-executive directors, and three independent non-executive directors, in compliance with Hong Kong listing rules[177] Human Resources - Employee compensation for the year was approximately RMB 443.3 million, up from RMB 339.1 million in 2020, with an average salary of RMB 123.6 thousand per year[92] Risks and Challenges - The company faces risks including high public medical insurance payment amounts, a shortage of professional medical personnel, and the potential inability to renew necessary business licenses[24] - The health sector is expected to see significant growth opportunities, driven by increased public awareness of mental health and an aging population, despite facing challenges from economic uncertainties and healthcare reforms[25] Shareholder Information - The company reported a total of 74,600,300 shares issued as of December 31, 2021, comprising 55,260,000 domestic shares and 19,340,000 H shares[131] - Mr. Guan Weili holds 18,350,250 domestic shares, representing approximately 40.07% of the domestic shares and 29.68% of the total issued share capital[131] - Ms. Wang Lianyue also holds 3,794,500 domestic shares, equivalent to approximately 40.07% of the domestic shares and 29.68% of the total issued share capital[131] - Ms. Wang Hongyue owns 3,984,350 domestic shares, which is about 10.46% of the domestic shares and 7.76% of the total issued share capital[131] - Mr. Xu Yongji holds 4,540,000 domestic shares, accounting for approximately 8.22% of the domestic shares and 6.09% of the total issued share capital[131]

溫州康寧醫院股份有限公司 Wenzhou Kangning Hospital Co., Ltd. (於中華人民共和國註冊成立的股份有限公司) 股份代號: 2120 ■ ２０２１ 中期報告 溫州康寧醫院股份有限公司 2021 中期報告 1 公司資料 2 財務摘要 4 管理層討論與分析 5 企業管治及其他資料 22 合併資產負債表 31 公司資產負債表 33 合併利潤表 35 公司利潤表 36 合併現金流量表 37 公司現金流量表 39 合併股東權益變動表 41 公司股東權益變動表 43 財務報表附註 45 釋義 117 目錄 頁次 | --- | --- | |-----------------------------------------|------------------------------------------| | | | | 溫州康寧醫院股份有限公司 2021 中期報告 | | | 公司資料 | | | 董事會 | 戰略與風險管理委員會 | | 執行董事 | 管偉立先生 （主席） | | | 鐘文堂女士 | | 管偉立先生 （董事長） | 秦 浩先生 | | 王蓮月女士 王紅月女士 | 監事 ...

溫州康寧醫院股份有限公司 Wenzhou Kangning Hospital Co., Ltd. (於中華人民共和國註冊成立的股份有限公司) 股份代號: 2120 202 年 度 報 णण 0 电子医院 ■ ■ ■ ■ M Hill 图 图 图 图 图] 0景看图 中六车み支 IT COLLECTION 目錄 管理層討論與分析6 頁次 公司資料2 財務摘要4 董事長致辭5 董事會報告 23 監事會報告 37 企業管治報告 38 董事、監事及高級管理層 55 審計報告 67 合併資產負債表 75 公司資產負債表 77 合併利潤表 79 公司利潤表 81 合併現金流量表 82 公司現金流量表 84 合併股東權益變動表 86 公司股東權益變動表 88 財務報表附註 90 釋義 204 2 2020 年度報告 溫 州 康 寧 醫 院 股 份 有 限 公 司 劉 寧先生 公司資料 | --- | --- | |-----------------------------------------------------------------------------------|---------------------- ...

溫州康寧醫院股份有限公司 Wenzhou Kangning Hospital Co., Ltd. (於中華人民共和國註冊成立的股份有限公司) 股份代號: 2120 A >>>>>> F >> 2020 中期報告 溫州康寧醫院股份有限公司 2020 中期報告 1 | --- | --- | --- | |--------------------|-------|-------| | | | | | | | | | | | 頁次 | | 公司資料 | | 2 | | 財務摘要 | | 4 | | 管理層討論與分析 | | 5 | | 企業管治及其他資料 | | 24 | | 合併資產負債表 | | 34 | | 公司資產負債表 | | 36 | | 合併利潤表 | | 38 | | 公司利潤表 | | 39 | | 合併現金流量表 | | 40 | | 公司現金流量表 | | 42 | | 合併股東權益變動表 | | 44 | | 公司股東權益變動表 | | 46 | | 財務報表附註 | | 48 | | 釋義 | | 121 | 2 溫州康寧醫院股份有限公司 2020 中期報告 公司資料 | --- | -- ...

溫州康寧醫院股份有限公司 Wenzhou Kangning Hospital Co., Ltd. (於中華人民共和國註冊成立的股份有限公司) 股份代號: 2120 14 | n B 线视频免费视 司 11 前 2019 年度報告 C la 目錄 頁次 公司資料2 財務摘要4 董事長致辭5 管理層討論與分析7 董事會報告 27 監事會報告 41 企業管治報告 42 董事、監事及高級管理層 59 審計報告 72 合併資產負債表 79 公司資產負債表 81 合併利潤表 83 公司利潤表 85 合併現金流量表 86 公司現金流量表 88 合併股東權益變動表 90 公司股東權益變動表 92 財務報表附註 94 釋義 212 2 2019 年度報告 溫 州 康 寧 醫 院 股 份 有 限 公 司 楊 揚先生 公司資料 | --- | --- | |-----------------------|----------------------------------------------------------------------------------| | | | | 董事會 | 監事會 | | 執行董事 | 孫方 ...

溫州康寧醫院股份有限公司 Wenzhou Kangning Hospital Co , Ltd. (於中華人民共和國註冊成立的股份有限公司) 股份代號: 21200 | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|---------------------------------|------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | life II wall be in a HTTP ITTER | 2 取宁医院 | | | | | | | | | | | | 9 中 期 報 告 頁次 公司資料2 財務摘要4 管理層討論與分析5 企業管治及其他資料 25 合併資產負債表 37 公司資產負債表 39 合併利潤表 41 公司利潤表 42 合併現金流量表 43 公司現金流量表 45 合併股東權益變動表 47 公司股東權益變動表 49 財務報表附註 51 釋義 120 ...

溫州康寧醫院股份有限公司 Wenzhou Kangning Hospital Co., Ltd. (於中華人民共和國註冊成立的股份有限公司) 股份代號: 2120 2018|午 目錄 頁次 公司資料2 財務摘要4 董事長致辭5 管理層討論與分析7 董事會報告 27 監事會報告 43 企業管治報告 44 董事、監事及高級管理層 61 審計報告 75 合併資產負債表 81 公司資產負債表 83 合併利潤表 85 公司利潤表 86 合併現金流量表 87 公司現金流量表 89 合併股東權益變動表 91 公司股東權益變動表 93 財務報表附註 95 釋義 215 | --- | --- | --- | |-------|-------------------------------------|------------------------------------------| | | 溫 州 康 寧 醫 院 股 份 有 限 公 司 | | | | | | | | 公司資料 | | | | 董事會 | 戰略與風險管理委員會 | | | 執行董事 | 管偉立先生 （主席） 黃 智先生 | | | 管偉立先生 （董事長） ...